SK Capital Partners, a private investment firm with a focus on the specialty materials, specialty chemicals and pharmaceuticals sectors, has purchased Apotex Pharmaceutical Holdings.
Apotex is a Canada-based pharmaceutical company focused on producing affordable medicines in therapeutic areas for patients.
“Apotex is a dynamic, entrepreneurial company with a strong track record of success, underpinned by its diversified product portfolio, robust pipeline of new launches and iconic brand,” says Aaron Davenport, managing director at SK Capital. “We feel incredibly privileged to have the opportunity to support Apotex with our deep experience in the pharmaceutical sector as it continues to research, develop and produce safe and affordable medicines for patients in Canada, the United States and around the world.”
RBC Capital Markets, Scotiabank, Jefferies LLC and Deutsche Bank Securities Inc. served as financial advisors to SK Capital and Kirkland & Ellis and McMillan LLP served as legal counsel.